Stay updated on Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial
Sign up to get notified when there's something new on the Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial page.

Latest updates to the Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision: v3.3.2 was added and v3.2.0 was removed on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedThe government funding notice banner was removed from the page; no changes to study content or eligibility details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedThe update appears to be minor UI tweaks with no addition or removal of core study content (title, conditions, interventions, primary outcomes, locations, or sponsor). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedAdded a government-operating-status notice and updated version to v3.2.0; removed v3.1.0.SummaryDifference4%

- Check78 days agoChange DetectedUpdated to Revision v3.1.0 and removed several specific drug-related topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the prior version.SummaryDifference0.4%

- Check93 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; removed the 'Back to Top' element.SummaryDifference0.2%

Stay in the know with updates to Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sublingual Dexmedetomidine in Schizophrenia-Associated Agitation Clinical Trial page.